What is a VMAT2 gene?
The vesicular monoamine transporter type 2 gene (VMAT2) has a crucial role in the storage and synaptic release of all monoamines, including serotonin (5-HT). To evaluate the specific role of VMAT2 in 5-HT neurons, we produced a conditional ablation of VMAT2 under control of the serotonin transporter (slc6a4) promoter.
How do VMAT2 inhibitors work?
VMAT2 inhibition is a mechanism that reduces dopamine stimulation without blocking D2 receptors. Thus, this action reduces the overstimulation of D2 receptors in the indirect pathway (on the right in Figure 4), resulting in less inhibition of the stop signal there.
What drug blocks VMAT?
By acting as a competitive antagonist, methamphetamine blocks the presynaptic cell’s ability to use VMAT for vesicular packaging.
What is VMAT inhibitor?
VMAT inhibitors are drugs that act to inhibit the vesicular monoamine transporters.
Do we have God’s DNA?
“You have the spiritual DNA of God,” said President Uchtdorf. And each of us can make a unique contribution to God’s work by choosing to serve His children in ways that are individual to each of us—and to them.
Is tetrabenazine a VMAT2?
Tetrabenazine (tet” ra ben’ a zeen) is an inhibitor of synaptic vesicular monoamine transporter 2 (VMAT2), the inhibition of which causes a depletion of neuroactive monoamines (serotonin, norepinephrine and particularly dopamine) in nerve terminals.
What are the diseases associated with the SLC18A2 gene?
GeneCards Summary for SLC18A2 Gene. SLC18A2 (Solute Carrier Family 18 Member A2) is a Protein Coding gene. Diseases associated with SLC18A2 include Parkinsonism-Dystonia, Infantile, 2 and Brain Dopamine-Serotonin Vesicular Transport Disease.
What is the role of SLC18A2 in prostate cancer?
SLC18A2 silencing by DNA hypermethylation and/or allelic loss is a frequent event in prostate cancer and a novel independent predictor of biochemical recurrence after prostatectomy These data suggest that up-regulated alpha-synuclein expression inhibits the activity of vesicular monoamine transporter-2.
Which is a significant association for SLC18A2 SNPs?
Nominal associations were indicated for 20 variants in six genes including an experiment-wise significant association from the combined effect of three SLC18A2 SNPs (rs363332, rs363334 and rs363338) with heroin dependence (pfinal = 0.047). SV2 was highly expressed in neuroblastoma (NB) and can thus be useful marker in NB diagnostics.
Is the SLC18A2 promoter protective for Parkinson disease?
Gain-of-function haplotypes in the SLC18A2 promoter are protective for Parkinson disease in women. Striatal VMAT2 expression was reduced significantly in dementia with Lewy bodies with or without Alzheimer’s disease, but was preserved in Alzheimer’s disease striatum, permitting postmortem distinction of the two pathologies.